Ind-Ra maintains stable outlook for pharmaceutical sector in FY21

06 Feb 2020 Evaluate

India Ratings and Research (Ind-Ra) has maintained the stable outlook for the pharmaceutical sector in the next financial year (FY21). It noted that the emerging price stability in the US generic market and the healthy domestic growth are likely to support cash generation for most large domestic pharma companies, leading to a margin improvement. It also stated that having made considerable investment into R&D and also capacity, the pharma firms will cut down on capital expenditure in current fiscal year (FY20).

According to the report, demand-supply situation in the US generic drug market favours complex generics, which also expects most large domestic pharma firms to aggressively invest in new product platforms to strengthen their market-readiness. Though, it said that this investment will constrain cash flows and hamper the deleveraging progress, new product launches and the overall price increase trend will ensure stable volume growth in the domestic market.

The report also pointed out that another positive for the market is the de-risking product portfolios from potential price controls and enhancing the presence in the chronic segment to drive investments for domestic market-focused drug makers. It expects active pharma ingredients supply originating from China to remain stable in FY21 despite the disruptions caused by the coronavirus outbreak. It added that any threat from China has the potential to impact manufacturing of critical drugs in the country.

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×